EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer

Kelli M Rasmussen, Vikas Patil, Chunyang Li, Christina Yong, Sreevalsa Appukkuttan, Jamie Partridge Grossman, Jay Jhaveri, Ahmad S Halwani

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2023.37272 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Network Open, 2023. Verfasst von Kelli M Rasmussen und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Utah School of Medicine, Salt Lake City. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Veterans. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Racial and ethnic disparities in prostate cancer are poorly understood. A given disparity-related factor may affect outcomes differently at each point along the highly variable trajectory of the disease.

Objective

To examine clinical outcomes by race and ethnicity in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) within the US Veterans Health Administration. Design, Setting, and Participants A retrospective, observational cohort study using electronic health care records (January 1, 2006, to December 31, 2021) in a nationwide equal-access health care system was conducted. Mean (SD) follow-up time was 4.3 (3.3) years. Patients included in the analysis were diagnosed with prostate cancer from January 1, 2006, to December 30, 2020, that progressed to nmCRPC defined by (1) increasing prostate-specific antigen levels, (2) ongoing androgen deprivation, and (3) no evidence of metastatic disease. Patients with metastatic disease or death within the landmark period (3 months after the first nmCRPC evidence) were excluded. Main Outcomes and Measures The primary outcome was time from the landmark period to death or metastasis; the secondary outcome was overall survival. A multivariate Cox proportional hazards model, Kaplan-Meier estimates, and adjusted survival curves were used to evaluate outcome differences by race and ethnicity.

Results

Of 12 992 patients in the cohort, 826 patients identified as Hispanic (6%), 3671 as non-Hispanic Black (28%; henceforth Black), 7323 as non-Hispanic White (56%; henceforth White), and 1172 of other race and ethnicity (9%; henceforth other, including American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander, unknown by patient, and patient declined to answer). Median time elapsed from nmCRPC to metastasis or death was 5.96 (95% CI, 5.58-6.34) years for Black patients, 5.62 (95% CI, 5.11-6.67) years for Hispanic patients, 4.11 (95% CI, 3.96–4.25) years for White patients, and 3.59 (95% CI, 3.23-3.97) years for other patients. Median unadjusted overall survival was 6.26 (95% CI, 6.03-6.46) years among all patients, 8.36 (95% CI, 8.0-8.8) years for Black patients, 8.56 (95% CI, 7.3-9.7) years for Hispanic patients, 5.48 (95% CI, 5.2-5.7) years for White patients, and 4.48 (95% CI, 4.1-5.0) years for other patients. Conclusions and Relevance The findings of this cohort study of patients with nmCRPC suggest that differences in outcomes by race and ethnicity exist; in addition, Black and Hispanic men may have considerably improved outcomes when treated in an equal-access setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantVeteransHumansMaleAndrogen AntagonistsBlack or African AmericanCohort StudiesEthnicityRetrospective StudiesWhiteHispanic or LatinoAmerican Indian or Alaska NativeAsianNative Hawaiian or Pacific Islander

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • University of Utah School of Medicine, Salt Lake City.
  • George E. Wahlen Veterans Health Administration, Salt Lake City, Utah.
  • Bayer US LLC, Whippany, New Jersey.
  • Huntsman Cancer Institute, Salt Lake City, Utah.

Zitieren

APA

Rasmussen, K. M., Patil, V., Li, C., Yong, C., Appukkuttan, S., Grossman, J. P., Jhaveri, J., & Halwani, A. S. (2023). Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.37272

Vancouver

Rasmussen KM, Patil V, Li C, Yong C, Appukkuttan S, Grossman JP, et al. Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.37272

BibTeX
@article{Rasmussen2023,
  author = {Rasmussen, Kelli M and Patil, Vikas and Li, Chunyang and Yong, Christina and Appukkuttan, Sreevalsa and Grossman, Jamie Partridge and Jhaveri, Jay and Halwani, Ahmad S},
  title = {Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2023.37272}
}
Kostenlos starten →